#Taiwan #New Taipei City #Cancer Immunotherapy #GlycoNex #Biotech Showcase

GlycoNex to Participate in Biotech Showcase 2025

GlycoNex, Inc. (stock code: 4168), a prominent clinical-stage biotechnology firm focusing on glycan-directed cancer immunotherapies, is thrilled to announce its participation in the Biotech Showcase 2025. This vital event will be held from January 13-15, 2025, at the Hilton San Francisco Union Square during the J.P. Morgan Week—a prime opportunity to connect with industry leaders and investors alike.

The leadership team at GlycoNex, including CEO Dr. Mei-Chun Yang, will actively engage with potential partners and investors. They plan to discuss various strategic initiatives alongside updates on the company's clinical trials and innovations in the field of glycan-targeted treatments and biosimilars.

In particular, Dr. Yang aims to underline notable advancements concerning GlycoNex's development pipeline. Among these are GNX1021, the company's promising antibody-drug conjugate (ADC), and SPD8, a denosumab biosimilar that is currently undergoing Phase 3 clinical trials. The primary objective is to showcase how GlycoNex's groundbreaking therapies could potentially redefine existing cancer treatment paradigms.

Event Details

• - Event: Biotech Showcase 2025
• - Date and Time: January 13-15, 2025
• - Location: Hilton San Francisco Union Square
• - Registration: Biotech Showcase Registration Options

About GlycoNex, Inc.

GlycoNex, Inc. is committed to developing advanced glycan-directed therapies that aim to effectively inhibit tumor growth while minimizing the associated side effects. The company's research and development are primarily led by GNX102, a humanized monoclonal antibody that specifically targets abnormal sugar molecules found in cancer cells. Remarkably, GNX102 has successfully completed Phase 1 clinical trials, yielding data that exhibit excellent safety profiles and promising efficacy.

Additionally, GlycoNex is expanding its portfolio with a range of antibody-drug conjugates (ADCs) that accurately attack cancer cells while sparing healthy tissues. The company operates from its headquarters in New Taipei City, Taiwan, ensuring a strong foundation for its innovative research.

As GlycoNex prepares for Biotech Showcase 2025, it looks to ignite interest and support for its revolutionary cancer therapies. For further inquiries or to arrange a meeting with GlycoNex during the event, please contact Seungwoo Yoo, Ph.D. at Tiberend Strategic Advisors, Inc.

Media Contact Information:

• - Investor Relations: Tiberend Strategic Advisors, Inc.
• - David Irish: [email protected]
• - Media Relations: Eric Reiss
• - Email: [email protected]

For more information on GlycoNex and its promising innovations in cancer therapy, visit GlycoNex Official Site.